277313-22-1

Upstream product

• 61874-04-2 (3-formyl-4-hydroxyphenyl)acetic acid methyl ester 
• 1576243-71-4 sodium salt of [4-hydroxy-3-(hydroxysulfomethyl)phenyl]acetic acid methyl ester 
• 14199-15-6 Methyl 4-hydroxyphenylacetate 

Downstream Products

• 277313-23-2 [3-bromo-5-formyl-4-(2-methoxy-ethoxymethoxy)-phenyl]-acetic acid methyl ester 
• 871266-65-8 methyl [5'-N-tert-butylsulfamoyl-5-(5-carbamimidoyl-1H-benzimidazol-2-yl)-6-hydroxy-2'-methoxybiphenyl-3-yl]acetate 
• 871266-69-2 [6,2'-bis-benzyloxy-5'-N-tert-butylsulfamoyl-5-(5-carbamimidoyl-1H-benzimidazolyl-2-yl)biphenyl-3-yl]acetic acid methyl ester hydrochloride 
• 871266-66-9 methyl [5-(5-carbamimidoyl-1H-benzimidazol-2-yl)-6-hydroxy-2′-methoxy-5′-sulfamoylbiphenyl-3-yl]acetate 
• 1597414-61-3 (R)-2-{2-[5-(5-carbamimidoyl-1H-benzimidazol-2-yl)-6,2'-dihydroxy-5'-sulfamoylbiphenyl-3-yl]acetylamino}succinic acid hydrochloride 
• 1597414-60-2 C₄₀H₃₆N₆O₉S*ClH 
• 1597414-62-4 C₄₀H₃₆N₆O₉S*ClH 
• 1597414-59-9 C₂₂H₁₉N₅O₆S*ClH 
• 1597414-58-8 C₄₀H₃₉N₅O₆S*ClH 
• 1597414-57-7 C₃₃H₃₃NO₇S 
• 871266-68-1 (6,2'-bisbenzyloxy-5'-N-tert-butylsulfamoyl-5-formylbiphenyl-3-yl)acetic acid methyl ester 
• 583031-89-4 (4-benzyloxy-3-bromo-5-formylphenyl)acetic acid methyl ester 
• 381210-42-0 [5-(5-cyano-1-methanesulfonyl-1H-indol-2-yl)-6-(2-methoxy-ethoxymethoxy)-3'-nitro-biphenyl-3-yl]-acetic acid methyl ester 

Relevant academic research and scientific papers

Optimization of a screening lead for factor VIIa/TF

The structure-based design and progression of a screening lead to a 3 nM factor VIIa/TF inhibitor with improved selectivity versus related enzymes is described.

FACTOR VIIA INHIBITOR

The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed.

LIQUID PHARMACEUTICAL COMPOSITION OF FACTOR VII POLYPEPTIDE

The invention concerns a liquid pharmaceutical composition comprising: A Factor VIIa polypeptide; A buffering agent suitable for keeping pH in the range of from about 5.5 to about 8.5; and An active site stabilizing agent, which is a compound exhibiting a

(Hetero)aryl-bicyclic heteroaryl derivatives, their preparation and their use as protease inhibitors

The present invention provides novel compounds of the Formula (I): A-B, its prodrug forms, or pharmaceutically acceptable salts thereof, wherein A represents a saturated, unsaturated, or a partially unsaturated bicyclic heterocyclic ring structure, and B represents an aryl or a heteroaryl group. Preferred compounds of the present invention comprise a benzimidazole or indole nucleus. The compounds of this invention are inhibitors of serine proteases, Urokinase (uPA), Factor Xa (FXa), and/or Factor VIIa (FVIIa), and have utility as anti cancer agents and/or as anticoagulants for the treatment or prevention of thromboembolic disorders in mammals.

FACTOR VIIA INHIBITOR

The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders

2-(2-HYDROXYBIPHENYL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE DERIVATIVES AS FACTOR VIIA INHIBITORS

The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed.

2-'5-(5-CARBAMIMIDOYL-1H-HETEROARYL)-6-HYDROXYBIPHENYL-3-YL!- CARBOXYLIC ACID DERIVATIVES AS FACTOR VIIA INHIBITORS

The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders. Processes for preparing these inhibitors are also disclosed.